









Sinergy between drugs and devices in the
fight against sudden cardiac death and
heart failure
Giuseppe Boriani 1*, Roberto De Ponti2, Federico Guerra 3, Pietro Palmisano 4,
Gabriele Zanotto5, Antonio D’Onofrio6, and Renato Pietro Ricci7
1Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Largo del Pozzo 71, 41121
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Abstract The impact of sudden cardiac death (SCD) in heart failure (HF) patients is important and prevention of SCD is a
reasonable and clinically justified endpoint if associated with a reduction in all-cause mortality.
According to literature, in HF with reduced ejection fraction, only three classes of agents were found effective in
reducing SCD and all-cause mortality: beta-blockers, mineralcorticoid receptor antagonists and, more recently,
angiotensin-receptor neprilysin-inhibitors. In the PARADIGM trial that tested sacubitril/valsartan vs. enalapril, the
20% relative risk reduction in cardiovascular deaths obtained with sacubitril/valsartan was attributable to reductions
in the incidence of both SCD and death due to HF worsening and this effect can be added to the known positive
effect of implantable cardioverter-defibrillators in appropriately selected patients.
In order to maximize the implementation of all the available treatments, patients with HF should be included in
virtuous networks with a dialogue between all the physician involved, with commitment by all these physicians for
appropriate decision-making on application of pharmacological and device treatments according to available
evidence, as well as commitment for drug titration before and after device implant, taking advantage from
remote monitoring, and with the safety of back up device therapy when indicated. There are potential synergistic
effects of drug therapy, with all the therapies acting on neuro-hormonal and sympathetic activation, but specifically
with sacubitril/valsartan, and device therapy, in particular cardiac resynchronization therapy, with added incremental
benefits on positive cardiac remodelling, prevention of HF progression, and prevention of ventricular
tachyarrhythmias.
...................................................................................................................................................................................................
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Introduction
Sudden cardiac death (SCD), defined as an unexpected death from
cardiac, causes following sudden cardiac arrest occurring within 1
h of the onset of acute symptoms continues to represent an
important clinical challenge for contemporary cardiology in view
of the variety of clinical conditions that may induce a risk of
SCD and of the many pathophysiological factors and mechanisms
that may lead to ventricular fibrillation, asystole or pulseless
electrical activity.1
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..In consideration of the complex interactions among the factors
involved in the arrhythmogenesis of SCD, including genetic factors
and the variable anatomical and functional myocardial substrates, as
well as the role of potential triggers, various approaches can be consid-
ered for improving survival through a reduction of SCD (Figure 1).2,3
Sudden cardiac death:
epidemiology and impact in heart
failure
Despite the reduction in cardiovascular mortality that occurred in
the last 20 years in western high-income countries as a result of im-
provement in prevention and care of ischaemic heart disease and
heart failure (HF),4 cardiovascular diseases remain the primary cause
of mortality in Europe and North America, with SCD accounting for
25% of the deaths due to cardiovascular diseases.3
The distribution of cases of SCD and the risk in absolute and
relative terms have great variations moving from the general popula-
tion to so-called ‘high-risk groups’ as shown in Figure 2 and this
constitutes the basis for the different strategies promoted for reduc-
ing SCD.1,3
The overall incidence of SCD in an unselected adult population is
1–2 per 1000 per year,1,3 but it is possible to identify, on the basis of
clinical factors, some subgroups of patients at higher relative risk of
SCD, for whom the incidence of SCD events at 1 year may be at least
10-fold greater than in the general population. These subgroups of
patients at high risk have been evaluated in randomized clinical trials
with the aim to assess the risk and cost–benefit ratio of a series of
pharmacological and non-pharmacological treatments such as beta-
blockers, amiodarone, or other antiarrhythmic agents, drugs for HF
or implantable cardioverter-defibrillators (ICDs) and cardiac
resynchronization therapy defibrillator (CRTD) devices. Patients
with coronary artery disease and previous myocardial infarctions
associated with left ventricular dysfunction as well as patients with
HF with systolic dysfunction belong to subgroups at high risk of SCD,
together with patients who already experienced a life-threatening
ventricular tachyarrhythmia or a cardiac arrest.5
The impact of SCD in HF patients is important since up to 50% of
the deaths occurring in patients with systolic HF are sudden and un-
expected, with HF associated with a risk of SCD six to nine times
Figure 1 Treatments to reduce sudden cardiac death by effecting the cardiac substrate or the ventricular arrhythmogenicity. ACE, angiotensin-
converting enzyme; AED, automated external defibrillator; ARB, angiotensin-receptor blocker; ARNI, angiotensin-receptor neprilysin inhibitor; ICD,
implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist.


































































































higher than the rate of SCD in the general population.3 It is note-
worthy that in the Metoprolol CR/XL Randomised Intervention Trial
in Congestive Heart Failure (MERIT-HF), the proportion of deaths
that resulted from SCD was proportionally higher in lower NYHA
(New York Heart Association) functional classes. In fact, in NYHA
class II, III, and IV patients, the proportion of SCD was 64%, 57%, and
33%, respectively, whereas 1-year absolute risk (cumulative inci-
dence) of SCD was 4%, 6%, and 6%, respectively.6 This observation is
important since indicates that SCD may occur in patients with rela-
tively preserved functional capacities and in whom the outcome in
terms of HF-related risk of death is favourable.
The chain of events and the mechanisms leading to SCD include
ventricular tachyarrhythmias, and, less frequently and usually in more
compromised patients, bradyarrhythmias, asystole, or pulseless elec-
trical activity, although the prediction in an individual patient is often
uncertain. The uncertainty is also related to the concept of SCD, an
entity which per se is characterized by a terminal event following a
sequence of events, while it is not characterized by a single mechan-
ism. A series of pathophysiological mechanisms (atherothrombosis
leading to acute ischaemia, neuro-hormonal activation, electrolyte
imbalances, etc.) may act as acute triggers, although the common re-
sult is an acute electrical or mechanical failure in remodelled and fi-
brotic ventricles.7 However, also genetic factors may play an
important role and especially in patients with preserved or mid-
range left ventricular ejection fraction (LVEF) their role may become
predominant for risk characterization and decision-making (Priori
et al.,3 Boriani et al.,8 and Zegkos et al.9).
Treatment of heart failure: goals
of treatments
The fundamental objectives for HF therapy are improving symptoms,
functional capacity and quality of life, slowing disease progression,
decreasing the need for hospitalization, and decreasing associated
mortality.10 Within the clinical scenario of HF, there are patients with
preserved or reduced LVEF, but only for the latter significant results
on outcomes have been demonstrated according to the rules of
evidence-based medicine. Indeed, to date, no randomized trial has
demonstrated a positive impact on mortality of any drug treatment in
patients with HF and preserved LVEF.11
In the general approach to HF with reduced LVEF prevention of
SCD is a reasonable and clinically justified endpoint if associated with
a reduction in all-cause mortality, thus avoiding a simple ‘conversion’
in the mode of death. Therefore, in the evaluation of the impact of
pharmacological and non-pharmacological treatments, the impact on
SCD will always be considered in parallel with the impact on all-
cause mortality. This approach should be applied to both traditional
pharmacological treatments and to the many treatments that were
proposed recently and whose validation requires the typical ap-
proach of evidence-based medicine.12
Impact of traditional drugs for
heart failure on sudden cardiac
death
Antiarrhythmic agents, also including amiodarone, have no role in
reducing SCD.2 In particular, amiodarone was investigated in SCD-
HeFT, a trial on the role of ICDs in primary prevention of SCD in HF
and no significant improvement in survival in the amiodarone arm vs.
the placebo arm of the SCD-HeFT emerged.13
A series of pharmacological treatments for HF have been tested in
randomized controlled trials with regard to the impact on all-cause
mortality, SCD, and other outcomes and the results are reported in
detail in Supplementary material online, Table S1.
Beta-blockers are a well-established component of optimized
medical treatment for HF and their effects include an improvement in
left ventricular structure and function (by decreasing ventricular size
and increasing LVEF) as well as an important role in the prevention of
arrhythmic events. Several trials have shown that beta-blockers re-
duce the risk of hospitalizations and death in HF patients. In a meta-
analysis of all randomized controlled trials examining the use of beta-
blockers vs. placebo/control for the prevention of SCD in HF
patients beta-blockers result to reduce the risk of SCD by 31%,
cardiovascular death by 29%, and all-cause mortality by 33%.14
Despite this substantial benefit, a residual risk of SCD persists during
long-term treatment with beta-blockers, thus suggesting the need for
additional preventive measures.
In a meta-analysis of published literature, mineralocorticoid
receptor antagonists, also called aldosterone antagonists, appeared
effective with a 19% risk reduction for SCD, as well as, with the same
amount, for all-cause mortality.15
A series of clinical trials have uniformly shown that angiotensin-
converting enzyme (ACE) inhibitors provide survival benefits in
patients with congestive HF or myocardial infarction. In a meta-
analysis of 15 randomized controlled trials comparing ACE inhibitors
with placebo in patients following acute myocardial infarction, ACE
inhibitor therapy resulted in a 20% reduction in the risk of death and
an 18% reduction in cardiovascular death and SCD (odds ratio: 0.80;
95%CI 0.70, 0.92).16 However, in the setting of HF, two systematic
Figure 2 The epidemiology of SCD, with a variable risk of SCD
according to patient subgroups in terms of incidence per year (left
panel) and total number of events per year (right panel). The catego-
ries of patients who are potential candidates for device therapy are
indicated (modified from Ref.1). CRTD, cardiac resynchronization
therapy defibrillator; ICD, implantable cardioverter-defibrillator.


































































































reviews did not find a significant effect of ACE inhibitors on the risk
of SCD.17,18
There is no evidence in support of a role of angiotensin-receptor
blockers (ARBs) on SCD in HF. In a meta-analysis, ARBs compared
with placebo had no significant effects on all-cause mortality and com-
pared with ACE inhibitors or in combination vs. ACE inhibitors alone,
no significant differences were found in all-cause mortality or SCD.15
According to a meta-analysis targeted to assess the effectiveness
of pharmacological interventions on SCD and all-cause mortality in
HF with reduced LVEF only three classes of agents were found effect-
ive: beta-blockers, mineralcorticoid receptor antagonists (MRA) and
more recently, as we will discuss later in this chapter, angiotensin-
receptor neprilysin-inhibitors (ARNIs).15
Ivabradine was found to reduce the composite of cardiovascular
death or hospital admission for worsening HF in patients who had
symptomatic HF and an LVEF of 35% or lower were in sinus rhythm
with heart rate 70 b.p.m. or higher.19 Ivabradine had a significant ef-
fect on pump failure death, which was reduced by 26%, but no signifi-
cant effect on SCD (Swedberg et al.19).
Recently, sodium-glucose co-transporter-2 (SGLT2) inhibitors20
and vericiguat21 were found effective in improving outcomes, with re-
gard to worsening HF or cardiovascular death, but the effect on SCD
need further evaluation.
Impact of devices on sudden
cardiac death in heart failure:
defibrillators and cardiac
resynchronization therapy
The role of ICD therapy as a rescue treatment was first conceived by
Dr Michel Mirowski over 40 years ago for secondary SCD prevention
in selected patients with documented ventricular tachyarrhythmias.22
The first ICD was implanted in 1980 and the approval of Food and
Drugs Administration was delivered in 1985 for patients who had
survived two episodes of cardiac arrest. Following the first pioneering
experiences, two key factors led to a progressive widespread imple-
mentation of the use of ICDs in selected patients: the technique of
implant in a subcutaneous pectoral pocket, without the need for
thoracotomy, and the validation, according to a series of randomized
controlled trials that tested the efficacy of ICD in reducing SCD and
improving overall survival, not only in the selective field of secondary
prevention but also in high-risk patients with left ventricular dysfunc-
tion without previous sustained ventricular tachyarrhythmias.13,23–31
The main results of the randomized controlled trials on the efficacy
of ICDs in improving survival are shown in Table 1. It is noteworthy
to stress that the use of all-cause mortality has the main endpoint of
most of the trial was a key factor in validating ICD therapy, since the
assumption that prevention of arrhythmic death or SCD translates
into reduction in all-cause mortality is not always true, as
demonstrated in the two trials that evaluated the ICD in the setting
of a recent myocardial infarction (IRIS and DINAMIT).32,33
For all the controlled studies on ICD in SCD prevention, the main
criterion for selecting patients at high risk of SCD was the presence
of a depressed left ventricular function. The evidence derived from
these trials, indicating that ICDs are effective in improving overall
survival at 2–5 years in appropriately selected patients with left ven-
tricular dysfunction at high risk of SCD, was the basis for the recom-
mendations for ICD implantation delivered by consensus
guidelines.3,10 The evidence of the benefit of ICD in non-ischaemic
patients has always been less solid than in patients with ischaemic
heart disease even if a meta-analysis including CAT, AMIOVERT,
DEFINITE, and the non-ischaemic cohort of SCD-HeFT found a stat-
istically significant benefit of ICD therapy on all-cause mortality, with
a 26% relative risk reduction,34 and this was the basis for the recom-
mendations of international consensus guidelines.3,10 The most re-
cent trial is the DANISH ICD study,35 a trial specifically targeted to
evaluate the impact of ICD implant in the setting of systolic dysfunc-
tion due to non-ischaemic cardiomyopathy. In a follow-up of more
than 5.5 years, no survival benefit occurred in the ICD group as com-
pared with usual care in the whole population, but a significant reduc-
tion in the risk of all-cause death was found in the subgroup of
patients younger than 68 years, with a 36% relative risk reduction. In
interpreting this study, it is important to consider that 58% of patients
received a device for cardiac resynchronization therapy (CRT).
A meta-analysis of the efficacy of ICD vs. control in the setting of pri-
mary prevention in patients with HF, clearly showed that, even
including the DANISH trial, the benefit of ICD on all-cause mortality
is confirmed in younger patients (below 65–70 years) with a relative
risk reduction of 32%, with important statistical significance.36 The
DANISH trial had the merit to explore with a dedicated randomized
controlled trial the complex setting of non-ischaemic cardiomyop-
athy, and although the full picture is not completely clear, we
improved our knowledge on how age may influence the effect of a
prophylactic ICD on all-cause mortality. Below the age of 65–70
years old implanting an ICD appears to be clinically useful also in non-
ischaemic cardiomyopathy and is therefore suggested by current
guidelines,3,10 even if this evidence is mostly derived from subgroup
analysis. Since age is only one component of the clinical picture of an
individual patient, there is need of improving outcome prediction
according to more detailed patient characterization including consid-
erations on renal function, diabetes, other comorbidities, and func-
tional status.37,38
Device therapy for SCD prevention experienced a substantial im-
provement with the clinical validation of CRT, initially found effective
in patients with moderate to severe HF, and more recently also in
mild HF, with clinically important benefits, as shown by the trials
shown in Table 2.30,31,39–47
According to these trials, use of CRT in appropriately selected
patients is associated with significant improvement in overall survival,
as well as provides favourable effects in terms of quality of life, exer-
cise capacity and is able to significantly reduce hospitalizations due to
HF.48
Unfortunately, no one trial with an adequate statistical power
compared the use of CRT with and without defibrillation capability,
and therefore decision-making on individual patients with regard to
the choice between CRT with only pacing (CRT-P) or with defibril-
lating capability (CRT-D) should be based on clinical considerations
including patient age, comorbidities, and clinical status.10,48–50
According to most recent guidelines, the recommendation for
implanting a CRT device in patients in sinus rhythm with moderate to
severe HF (NYHA functional class III–IV) (the setting where the effi-
cacy of CRT was initially validated) are the following: CRT is strongly

























recommended in case of left bundle branch block (LBBB) with QRS
duration >150 ms, while a lower strength of recommendations is
released when QRS duration is between 130 and 150 ms, especially if
not associated with LBBB.48
Moreover, according to guidelines, device therapy for primary pre-
vention of SCD is indicated if LVEF remains reduced, i.e. <_35%, after
at least 3 months of optimal medical therapy for HF with agents
acting on sympathetic and neuro-hormonal activation such as
beta-blockers, ACE inhibitors, ARBs, and MRA.10,48 In view of the
period of time when ICD trials were conducted, it is clear that they
do not reflect the evolution of pharmacological and interventional
treatments occurred in the last years, but on the other hand, it will be
questionable, in ethical terms, to perform new trials enrolling patients
from current daily practice, with randomization of patients at high
risk of SCD to ICD vs. no-ICD treatment. Moreover, with all the limi-
tations of non-controlled studies, at least two large-scale prospective
registries that evaluated prophylactic ICD implant in HF patients
using propensity score matching found a lower long-term mortality
....................................................................................................................................................................................................................
Table 1 Main controlled trials on implantable cardioverter-defibrillators vs. amiodarone or other controls in
secondary and primary prevention of sudden cardiac death out of the setting of recent myocardial infarction




AVID: Antiarrhythmics Versus Implantable
Defibrillators (1997)19
1016 ICD vs. AADs (amio-
darone in 96%)
18 All-cause death <0.02 31%
CIDS: Canadian Implantable Defibrillator
Study (2000)21
659 ICD vs. amiodarone 36 All-cause death 0.142 20%
Arrhythmic death 0.094 33%
CASH: Cardiac Arrest Study Hamburg
(2000)22
288 ICD vs. amiodarone,
propafenone or
metoprolol
57 All-cause death 0.081 23%
Meta-analysis AVID, CASH, CIDS (2000)23 1866 ICD vs. amiodarone 28 All-cause death <0.001 27%
Arrhythmic death <0.001 51%
Non-arrhythmic death NS 7%
Primary prevention trials
MADIT: Multicenter Automatic Defibrillator
Implantation Trial (1996)18
196 ICD vs. control 27 All-cause death 0.009 54%
MUSTT: Multicenter Unsustained
Tachycardia Trial (1999)20




39 Cardiac arrest or
arrhythmic death
0.04 27%




All-cause death <0.001 60%
MADIT II: Multicenter Automatic
Defibrillator Implantation Trial II (2002)24
1232 ICD vs. control 20 All-cause death 0.016 31%
COMPANION: Comparison of Medical
Therapy, Pacing, and Defibrillation in
Heart Failure Trial (2004)25
1634 CRT-D vs. control 16 All-cause death or
hospitalization
0.01 20%
All-cause death 0.003 36%
SCD-HeFT: Sudden Cardiac Death in Heart
Failure Trial (2004)11
2521 ICD vs. amiodarone
vs. placebo







Defibrillator Implantation Trial – Cardiac
Resynchronization Therapy (2009)26
1820 ICD vs. CRT-D 54 All-cause death or HF
event
0.001 36%
HF event <0.001 41%
DANISH ICD: Danish Study to Assess the
Efficacy of ICDs in Patients with Non-is-
chaemic Systolic Heart Failure on
Mortality(2016)29
1116 ICD vs. control (CRT-
D in 58%)
67.6 All-cause death 0.28 13%a
AADs, anti-arrhythmic drugs; CI, confidence interval; CRT-D, cardiac resynchronization therapy-defibrillator; EPS, electrophysiologic study; HF, heart failure; HR, hazard ratio;
ICD, implantable cardioverter-defibrillator; RRR, relative risk reduction.
aHazard ratio 0.87 (95% CI 0.68–1.12; P = 0.28) for ICD vs control in the whole cohort, but among patients < 68 years HR 0.64 (95% CI 0.45–0.90; P = 0.01).




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in ICD patients vs. no-ICD patients,51,52 together with an underuse of
ICD therapy.51
The wearable cardioverter defibrillator is a non-invasive option
that has been used in patients at risk of SCD not eligible for an ICD.
Moreover, the wearable ICD has been proposed for short-term use
in patients with an high risk of ventricular tachyarrhythmias that is
considered to be transient with some possibility to diminish over
time (i.e. severe myocarditis or severe coronary disease prior to
revascularization) or when implant of a transvenous ICD is contrain-
dicated (i.e. infection requiring ICD system removal). Data on safety
of the wearable defibrillator have been collected in a prospective
registry (WERIT-II) and during a median duration period of 90 days
the rate of sustained ventricular tachyarrhythmias was 3% among
patients with ischaemic cardiomyopathy and 1% among non-
ischaemic patients (P = 0.02).53
Recently, the role of the wearable cardioverter defibrillator was
tested in a randomized controlled trial, the VEST study that random-
ized 2302 patients with recent myocardial infarction and LVEF <35%
to a wearable defibrillator or watchful waiting. No reduction in the
primary endpoint of SCD or 90-day arrhythmic death, while the re-
duction in total mortality found in the group with a wearable defibril-
lator became insignificant after correction with various approaches of
the multiplicity of tests.54 In this trial, problems of adherence to wear-
ing the defibrillator complicated the ability to demonstrate a clinical
benefit and only the on-treatment and per-protocol analyses showed
a benefit in patients selected for high compliance to the wearable
defibrillator.55
Sacubitril/valsartan: impact on
cardiovascular mortality and on
sudden cardiac death
One of the most important innovation of recent years is the
evidence of benefit of ARNIs and specifically of sacubitril/valsartan, at
present the only agent available for clinical practice. The use of sacu-
bitril/valsartan has been validated by the PARADIGM trial. In this
Figure 3 Effects of sacubitril/valsartan vs. enalapril on a series of clinical outcomes in the PARADIGM-HF trial. Data are reported as hazard or rate
ratios and 95% confidence intervals. From Refs.56–58. CV, cardiovascular; ED, emergency department; HF, heart failure.
Figure 4 Data from PARADIGM-HF trial on the effect of sacubi-
tril/valsartan vs. enalapril in the subgroups without (n = 7156) and
with defibrillator therapy back-up (with an ICD or CRTD device)
(n = 1243).62 No significant interaction was found (Pint was not sig-
nificant). CRTD, cardiac resynchronization therapy defibrillator; CV,
cardiovascular; HF, heart failure; ICD, implantable cardioverter-
defibrillator.


































































































prospective randomized trial, 8442 patients with chronic HF, NYHA
functional class II–IV, with LVEF <_35% (<_40% for the first of the 3
years of patient enrolment), were evaluated to compare the effect of
sacubitril/valsartan 97/103 mg b.i.d. compared with enalapril 10 mg
b.i.d., in addition to conventional treatment, in delaying time to first
occurrence of either cardiovascular death or HF hospitalization.56
Sacubitril/valsartan treatment was associated to a 20% reduction of
the primary endpoint, with a 21% reduction of HF hospitalizations
and 20% reduction of death for cardiovascular causes.56 Over 80% of
deaths in PARADIGM-HF had a cardiovascular cause, of which 45%
were due to SCD. Among the causes of death observed in
PARADIGM-HF, SCD accounted for 35.2% of all the deaths
occurred in the sacubitril/valsartan arm and for 37.2% of all the
deaths occurred in the enalapril arm.57
A complete picture of the benefits highlighted by the PARADIGM-
HF trial is shown in Figure 3, where a series of endpoint of high clinical
significance resulted favourably and significantly improved by sacubi-
tril/valsartan compared with enalapril. As expected, non-
cardiovascular mortality was not affected, thus stressing the need for
multidisciplinary interventions on the most important comorbidities,
related to diabetes, kidney function, etc.58–61
Sacubitril/valsartan in patients
with defibrillators or cardiac
resynchronization therapy: the
potential for a synergistic effect
In the PARADIGM-HF trial, sacubitril/valsartan therapy was associ-
ated to a significant 20% reduction of SCD when compared with ena-
lapril therapy and the reduction of overall mortality and SCD was
observed both in patients with and without ICD or CRT-D
(Figure 4).62 Unexpectedly, considering that all patients enrolled in
the PARADIGM-HF trial had an LVEF <_35%, only 15% of them had
an implanted ICD and 7% a CRT device. Of note, both survival curves
for death for cardiovascular causes and for SCD began to diverge
early in patient without ICD/CRT-D and late (after 2 years) in those
with ICD/CRT-D.62
The benefits of sacubitril/valsartan in SCD reduction led to investi-
gate in detail the interaction between ARNI e device therapy in
patients with HF. De Diego et al.63 investigated the effect of
angiotensin-neprilysin inhibition on ventricular arrhythmias com-
pared with angiotensin inhibition in 120 HF with reduced LVEF
patients with an ICD and remote monitoring. Appropriate shocks sig-
nificantly decreased in the sacubitril valsartan arm from 6.7% to 0.8%.
Furthermore, sustained and non-sustained ventricular tachycardia
episodes significantly decreased. No differences were observed in
atrial fibrillation incidence. Similar results have been reported by
Martens et al.64 Possible explanation for the antiarrhythmic effects
of sacubitril/valsartan include the increase of beneficial natriuretic
peptides leading to diuresis, vasodilatation, decrease of sympathetic
tone, and of aldosterone levels. Furthermore, cardiac fibrosis
suppression and structural remodelling as well as wall stress
reduction may play a role.63–66
Another potential synergistic effect of drug therapy with sacubitril/
valsartan and device therapy, in particular CRT, is the incremental
benefits on positive cardiac remodelling and prevention of HF pro-
gression. However, data from registries have shown that up to 30%
of CRT patients do not receive guideline-directed optimal medical
therapy.67 As a matter of fact, it has been clearly demonstrated that
optimal medical therapy is associated with better survival in patients
with implanted ICD and CRT.68,69 Furthermore, continuous remote
monitoring of patients with implanted devices offers a unique oppor-
tunity to early detect HF impairment and to timely optimize medical
therapy.70–72
Considerations about guideline-
adherent medical and device
therapy in HF
• There are good reasons to support a synergistic effect between
electrical treatments and guideline-adherent pharmacological ther-
apy, with specific focus on sacubitril/valsartan, the last agent intro-
duced in daily practice. The clinical target should be to implement
these treatments in all the patients with a guideline-adherent indi-
cation, in order to ensure the most effective treatments for
improving outcomes, according to a series of considerations:
• SCD may occur unexpectedly and despite the reduction that can
be obtained with sacubitril/valsartan, combined with beta-blockers
and MRAs, a residual risk persists and therefore the back-up of
ICD therapy for termination of malignant ventricular tachyarrhyth-
mias may ensure the best protection at long term and maximize
cardiovascular outcomes for patients who have an indication
according to guidelines. 3,10
• Implant of a device such as ICD, CRT-D, or CRT-P according to
guidelines indications should not be postponed beyond the period
indicated by guidelines (3 months of optimal medical treat-
ment)3,10 and according to national rules for prescribing sacubitril/
valsartan the latter treatment can be implemented either before
or after device implant.
• An extension of the period for implementation and titration of
beta-blockers, MRAs, ACE inhibitors, ARBs, or sacubitril/valsartan
up to 9–12 months, rather than the usual 3 months waiting period,
sometimes applied in case of new-onset HF in order to maximize
left ventricular remodelling and increase LVEF, implies a small but
significant risk of SCD (2–4%)73,74 that may be particularly dramat-
ic in young patients. Therefore, patients at higher risk of SCD
(patients with severe left ventricular dysfunction, patients with
non-sustained ventricular tachycardia) and younger patients should
be absolutely prioritized for not delaying ICD implant.
• It is absolutely important to titrate beta-blockers, ACE inhibitors,
ARBs, or sacubitril/valsartan up to maximum tolerated doses and
this process has to be applied both before and after implant of an
electrical device,75,76 also with the advantage of the back-up of
anti-bradycardia pacing provided by electrical devices in case of
excessive bradycardia following an attempt of dosage increase for
a beta-blocker.77
• An improvement in LVEF during long-term follow-up is a frequent
finding after implant of an ICD, even above 35%, but it is not
associated with lack of appropriate device interventions for
malignant ventricular tachyarrhythmias thus suggesting that the
risk of ventricular tachyarrhythmias and SCD is modulated by
pharmacological treatments, but a residual risk persists, along with


































































































time, that in appropriate patients may surely benefit from the res-
cue role of a back-up ICD.78–81
• In patients implanted with an ICD or a CRT-D appropriate ICD
shocks (especially when clustered into electrical storms) are asso-
ciated with a significant increase in the subsequent risk of all-cause
death82,83 and therefore the occurrence of shocks, even if appro-
priate, should be considered a warning sign of a worsening prog-
nosis.84 Implementation of sacubitril/valsartan is in these cases
absolutely appropriate in order to implement the favourable
effects of this agent on ventricular tachyarrhythmias.63,64,85 and
maximize the ability to improve outcome as well as quality of
life86 and ICD electrical atrial parameters.87
• The process of reduction of left ventricular volumes, with reversal
of left ventricular geometry alterations and with improvement of
systolic function occurring in HF after neuro-hormonal blockade
(the so-called ‘left ventricular reverse remodelling’) is a key factor
for outcome improvement, also in terms of prevention of
SCD88,89 and is more pronounced with ARNI as compared with
ACE inhibitors, thus supporting the rationale for instituting sacubi-
tril/valsartan in all the patients who can be eligible for ARNI
treatment.90
• CRT is a very effective non-pharmacological treatment in appro-
priately selected patients,91,92 and structural left ventricular reverse
remodelling is a key factor in determining the clinical and outcome
benefits at long term.93
• CRT is primarily indicated in patients with LBBB and the haemo-
dynamic benefit is related to correction of the electro-mechanical
associated with the conduction disturbance. It is noteworthy that
LBBB-associated remodelling appears to result in a limited reverse
remodelling during guideline-adherent pharmacological treatment
as compared with non-LBBB patients, thus indicating that in
patients with LBBB implant of a CRT device, following implemen-
tation of drug treatment for a reasonable period of time, should
not be deferred, waiting for an improvement of LVEF induced by
pharmacological treatments that has a very limited chance to
occur.94 Moreover, after implant of a CRT device, there is the
possibility of an increase in systolic blood pressure that may allow
initiation of drugs that were not tolerated or could not be admin-
istered for hypotension before implant, such as sacubitril/valsartan,
in line with the concept of additive, if not synergistic effects be-
tween CRT and ARNI.
• Remote monitoring offers the possibility to detect signals and
measures data from pacemakers, ICD, and other implantable devi-
ces. The aim is to detect impending HF decompensation and to
consequently take decisions on drug dosages and patients care.
Unfortunately, the high expectations of benefit were not con-
firmed by the randomized studies performed so far.95 However,
some prospective non-controlled studies recently performed, indi-
cate a positive impact on patient management with the most re-
cent device algorithms able to collect data from multiple
sensors,71,96 with need to better assess the impact of these tech-
nologies through randomized controlled studies for a more
detailed assessment.
• The dialogue and synergistic actions and decisions of cardiologists
involved in electrophysiology and device therapy and cardiologists
dedicated to HF care is important and will continue to be import-
ant for future treatments, either pharmacological or non-
pharmacological.12
• The value of ICD back-up to minimize the residual risk of SCD in
patients with an established indication and who are candidate to
initiate sacubitril/valsartan is further supported by some data on
the initial period of treatment with sacubitril/valsartan.97–99 These
data are observational and related to case reports or to a collec-
tion of pharmacovigilance reports and even if they do not put into
question the evidence of benefit of sacubitril/valsartan on SCD at
long term, are of interest for considerations on the time course
and the determinants of the effect of this agent on arrhythmogen-
esis and the cardiac substrate. The reverse left ventricular remod-
elling induced by sacubitril/valsartan may actually be the key
mechanism for reducing SCD7 but some months are required for
this process to occur, thus with exposure to a residual risk of
SCD especially in the first 3 months after treatment initiation.99
These data, even if observational, strongly suggest the advantages
of a combined use or sacubitril/valsartan and ICD, when
indicated according to guidelines, without delaying the device im-
plant, in order to fully achieve the benefits that these two treat-




of drugs and devices in patients at
risk
In view of the increasing burden of cardiovascular disease and specif-
ically HF, there is need for improving knowledge on treatments for
HF and SCD prevention of proven efficacy according to evidence-
based medicine, as implemented in consensus guidelines recommen-
dations. General practitioners, internists, physicians involved in HF
care and emergency medicine, as well as electrophysiologists should
dialogue and collaborate more strictly, in a perspective of patient-
centred care, organizing network for appropriate patient referral
both for pharmacological and device therapy. Indeed, it has been
reported that in Sweden an important and substantial awareness gap
was found through a survey among the medical community, thus
explaining the limited referral rates and utilization of device therapy
in HF patients.100
Conclusions
In order to maximize the implementation of all the available treat-
ments, either pharmacological or non-pharmacological, patients with
HF should be included in virtuous networks with a dialogue between
all the physician involved, specifically cardiologists involved in electro-
physiology and device therapy and cardiologists dedicated to HF
care.
A strict collaboration between specialists is absolutely needed
since there are potential synergistic effects between drug therapies
acting on neuro-hormonal and sympathetic activation (specifically
sacubitril/valsartan) and device therapy, in particular CRT, with bene-
fits in terms of reverse cardiac remodelling, slowing of HF progres-
sion and prevention of ventricular tachyarrhythmias.
It is absolutely important to titrate beta-blockers, ACE inhibitors,
ARBs, or sacubitril/valsartan up to maximum tolerated doses and this
process has to be applied both before and after implant of an electric-
al device.


































































































An extension of the period for implementation and titration of
beta-blockers, MRAs, ACE inhibitors, ARBs, or sacubitril/valsartan up
to 9–12 months, rather than the usual 3 months waiting period,
implies a small but significant risk of SCD (2–4%)73,74 that may be par-
ticularly dramatic in young patients. Therefore, patients at higher risk
of SCD (patients with severe left ventricular dysfunction, patients
with non-sustained ventricular tachycardia) and younger patients
should be prioritized for not delaying ICD implant.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology online.
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C, Sousa-Casasnovas I, Fernández-Avilés F, Martı́nez-Sellés M. Ventricular ar-
rhythmic storm after initiating sacubitril/valsartan. Cardiology 2018;139:
119–123.
98. Okutucu S, Oto A. Electrical storm after initiating sacubitril/valsartan: arrhythmic
paradox. Cardiology 2019;142:24–25.
99. Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with
sacubitril/valsartan in the real world: emerging signals to target preventive strat-
egies from the FDA adverse event reporting system. Eur J Prev Cardiol 2020;
204748732091566. doi: 10.1177/2047487320915663.
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